Kales, A; Scharf, M.; Kales, J. (1978). “Rebound insomnia: a new clinical syndrome”. Science201 (4360): 1039–1041. doi:10.1126/science.684426. PMID684426.
Kales A; Scharf MB, Kales JD, Soldatos CR. (1979-04-20). “Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines”. JAMA : the Journal of the American Medical Association241 (16): 1692-5. doi:10.1001/jama.241.16.1692. PMID430730.
Adam K; Oswald I (May 1989). “Can a rapidly-eliminated hypnotic cause daytime anxiety?”. Pharmacopsychiatry22 (3): 115-9. doi:10.1055/s-2007-1014592. PMID2748714.
Fontaine, R; Beaudry, P; Le, Morvan, P; Beauclair, L; Chouinard, G (July 1990). “Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety.” (PDF). International clinical psychopharmacology5 (3): 173-83. doi:10.1097/00004850-199007000-00002. ISSN0268-1315. PMID2230061.
Griffiths RR, Lamb RJ, Sannerud CA, Ator NA, Brady JV (1991). “Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons”. Psychopharmacology (Berl.)103 (2): 154-61. doi:10.1007/BF02244196. PMID1674158.
Kales, A; Scharf, M.; Kales, J. (1978). “Rebound insomnia: a new clinical syndrome”. Science201 (4360): 1039–1041. doi:10.1126/science.684426. PMID684426.
Kirkwood CK (1999). “Management of insomnia”. J Am Pharm Assoc (Wash)39 (5): 688-96; quiz 713?4. PMID10533351.
Altamura AC, Colacurcio F, Mauri MC, et al. (1989). “[Controlled clinical study on the effect of quazepam versus triazolam in patients with sleep disorders]” (Italian). Minerva Psichiatr30 (3): 159-64. PMID2691808.
Veje JO; Andersen K, Gjesing S, Kielgast H. (1989-08-21). “Prescription of tranquilizers and hypnotics in the municipality of Holbaek”. Ugeskr Laeger151 (34): 2134-6. PMID2773144.
Kales A; Scharf MB, Kales JD, Soldatos CR. (1979-04-20). “Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines”. JAMA : the Journal of the American Medical Association241 (16): 1692-5. doi:10.1001/jama.241.16.1692. PMID430730.
Adam K; Oswald I (May 1989). “Can a rapidly-eliminated hypnotic cause daytime anxiety?”. Pharmacopsychiatry22 (3): 115-9. doi:10.1055/s-2007-1014592. PMID2748714.
Fontaine, R; Beaudry, P; Le, Morvan, P; Beauclair, L; Chouinard, G (July 1990). “Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety.” (PDF). International clinical psychopharmacology5 (3): 173-83. doi:10.1097/00004850-199007000-00002. ISSN0268-1315. PMID2230061.
Terao T; Tani Y. (1988-09-01). “Two cases of psychotic state following normal-dose benzodiazepine withdrawal”. J Uoeh.10 (3): 337-40. PMID2902678.
Griffiths RR, Johnson MW (2005). “Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds”. J Clin Psychiatry66 Suppl 9: 31-41. PMID16336040.
Griffiths RR, Lamb RJ, Sannerud CA, Ator NA, Brady JV (1991). “Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons”. Psychopharmacology (Berl.)103 (2): 154-61. doi:10.1007/BF02244196. PMID1674158.
Abraham, John, "Transnational....: Adverse Drug Reactions and the Crisis Over the Safety of Halcion [triazolam] in the Netherlands and the UK. Social Science and Medicine: 55 (2002)1671-1690. http://www.sussex.ac.uk/sociology/documents/ssm02.pdf[リンク切れ]
Fontaine, R; Beaudry, P; Le, Morvan, P; Beauclair, L; Chouinard, G (July 1990). “Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety.” (PDF). International clinical psychopharmacology5 (3): 173-83. doi:10.1097/00004850-199007000-00002. ISSN0268-1315. PMID2230061.
yakugai.gr.jp
薬害オンブズパースン会議 (27 August 2002). ハルシオンの患者用説明書についての要望書(pdf) (Report). 2016年6月15日閲覧。